Abstract
AbstractBackgroundThis study aimed to calculate the seroconversion rate of the CoronaVac vaccine in healthcare workers (HCWs) after immunization.MethodsSerum samples from 133 HCWs from Southern Brazil were collected one day before (Day 0) and +10, +20, +40, + 60, +110 days after administering the vaccine’s first dose. Immunoglobulin G (IgG) was quantified using immunoassays for anti-N-protein (nucleocapsid) antibodies (Abbott, Sligo, Ireland) and for anti-S1 (spike) protein antibodies (Euroimmun, Lübeck, Germany).ResultsSeroconversion by day 40 occurred in 129 (97%) HCWs for the S1 protein, and in 69 (51.87%) HCWs for the N protein. An absence of IgG antibodies (by both methodologies), occurred in two (1.5%) HCWs undergoing semiannual rituximab administration, and also in another two (1.5%) HCWs with no apparent reason.ConclusionThis study showed that CoronaVac has a high seroconversion rate when evaluated in an HCW population.FundingThis work was supported by the PROPLAN/Federal University of Paraná, Curitiba-Paraná, Brazil; FINEP, Funder of Studies and Projects, Ministry of Science, Technology and Innovation, Brazil Institutional Network, Project: Laboratories for Diagnostic Tests for COVID-19 (0494/20).
Publisher
Cold Spring Harbor Laboratory
Reference30 articles.
1. World Health Organization (WHO), WHO Coronavirus (COVID-19) Dashboard. [cited 2021 Jul 5] Available from: https://covid19.who.int/
2. Golob JL , Lugogo N , Lauring AS , Lok AS. SARS-CoV-2 vaccines: a triumph of science and collaboration. JCI Insight. 2021 Apr 6;
3. Kumar SU , Priya NM , Priyanka SRN , Nikita K , Thirumal JD. A review of novel coronavirus disease (COVID LJ 19): based on genomic structure, phylogeny, current shreds of evidence, candidate vaccines, and drug repurposing. 3 Biotech. 2021;
4. SARS-CoV-2 vaccines: Lights and shadows;Eur J Intern Med [Internet],2021
5. Biochemical characterization of SARS-CoV-2 nucleocapsid protein;Biochem Biophys Res Commun,2020